The CITIDEMAGE Study: Combined Treatment with a Cholinergic Precursor in Dementia Patients
Abstract
(ISSN 2638-1311)
OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Aging and Alzheimer’s Disease
Submission Deadline: February 15, 2020 (Closed) Submit Now
About This Topic
Alzheimer's disease (AD) is the most common form of dementia, accounts for 60-80 % of dementia cases. Currently, ~ 50 million people are believed to be living with AD and other dementia, which are estimated to be reached at 150 million by 2050. Aging is the most predominant factors for AD onset. The onset prevalence increases from 16% at 65-74 years age group to 81% among older people of 75 years and over. While the initial symptoms of AD vary person to person, the cognitive impairment (memory decline) is typically one of the first noticeable AD clinical symptom. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioral issues. The cost of dementia care worldwide has estimated around US$ 1 trillion per year. This special issue will seek to address a broad area of topics related to the causes, care and management of AD, and discuss interventions/solutions to prevent AD among aging population.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
The CITIDEMAGE Study: Combined Treatment with a Cholinergic Precursor in Dementia Patientsby
Pietro Gareri
,
Antonino Maria Cotroneo
,
Giuseppe Orsitto
,
Nicola Veronese
and
Salvatore Putignano
Abstract Certain previous studies have demonstrated the benefits of the addition of citicoline, a cholinergic precursor, to acetylcholinesterase inhibitors (AchEIs) or memantine in patients with Alzheimer’s disease (AD). The present study showed the effectiveness of oral citicoline plus AchEIs plus memantine in [...] |
Glial Alterations in Aging and Alzheimer’s Disease: A Novel Basis to Understand, Prevent and Treat the Degenerative ProcessAbstract Neurons, from the time of their birth until their death, are always accompanied by neuroglial cells, maintaining very close morphological and functional relationships among themselves. Classically three main neuroglial families have been considered within the central nervous system (CNS): astroglia, oligodendroglia, and microglia. However [...] |
Biomaterial to Improve Drug Delivery in Alzheimer's Disease: Linking Major Pathogenic PathwaysAbstract Aging, hypertension, diabetes, obesity, atherosclerosis, traumatic brain injury, and other factors can all synergistically promote diverse pathological mechanisms. These risk factors trigger widespread inflammation and oxidative stress, both of which can lead to blood-brain barrier (BBB) disruption. These pathological cascades lead to neuronal [...] |
Alzheimer's Disease: Parsing the Pathways Leading to the Disease Based on the Spirochete/Biofilm HypothesisAbstract A pathway which highlighted spirochetes (Borrelia burgdorferi and dental treponemes) that made biofilms which led to Alzheimer’s disease has recently been promulgated. All the Alzheimer’s disease, on which this pathway was based, had been specifically confirmed both clinically and pathologically. This current work will show putative and [...] |
Cortical Activity and Rhythmic Patterns in Mouse Models of Aging and Alzheimer’s DiseaseAbstract Aging and Alzheimer’s disease (AD) have been reported to induce changes in the cerebral cortex circuits. The present review aims to study these alterations by reviewing emergent cortical activity with a focus on the rhythmic patterns. The rationale for this approach was two-fold: (i) emergent rhythmic activity integrates cellular [...] |
TOP